Funded Research Projects
We are the leading source for enabling and accelerating groundbreaking research at the intersection of AI and health.
Our services and solutions directly lead to grants and other project funding for U-M researchers.
Featured Funded Research
Research Funded With AI & Digital Health Innovation Support
| Project Title | Funding | Funding Start | Funding Period | Funding Source | Principal Investigator(s) |
|---|---|---|---|---|---|
| FY25-(OPENED-UM): Opioid Prescribing Engagement Network Emergency Department Project | $270,833 | October, 2024 | 1 year | CDC | C. Brummett, M. Bicket |
| Michigan Opioid Prescribing Engagement Network (M-OPEN) | $3,787,800 | October, 2024 | 1 year | CMS | C. Brummett, M. Bicket, A. Bohnert |
| Cultivating Recovery: A Pilot Study of Digital Contingency Management for Co-occurring Opioid and Alcohol Use Disorder | $1,170,000 | September, 2024 | 3 years | NIH | A. Fernandez |
| COMPASS: A comprehensive mobile precision approach for scalable solutions in mental health treatment | $17,927,886 | July, 2024 | 4.83 years | NIH | S. Sen, A. Bohnert, L. Fritsche |
| Ultrasensitive Detection of a "Binary" Blood Biomarker for Endometrial Cancer | $587,862 | July, 2024 | 2 years | Department of Defense | C. Wu |
| EXP3 - Micro-randomized trial to assess brief, just-in-time interventions for reducing short-term suicide risk | $170,904 | June, 2024 | 3 years | NIH | W. Dempsey |
| CS585 development in cardiovascular research | $544,947 | May, 2024 | 1 year | Cereno Scientific AB | M. Holinstat |
| CAREER: From Fragile to Fortified: Harnessing Causal Reasoning for Trustworthy Machine Learning with Unreliable Data | $600,000 | April, 2024 | 5 years | National Science Foundation | M. Makar |
| Risk-stratified care for thyroid cancer survivors | $3,311,025 | April, 2024 | 5 years | NIH | M. Haymart |
| Developing a Spatio-Temporal Model to Assess the Impact of Greening Projects on Crime Reduction | $11,530 | January, 2024 | 1 year | Global Impact | Y. Li |
| Statistical Methods for Integrating Mixed-type Biomarkers and Phenotypes in Neurodegenerative Disease Modeling | $162,543 | January, 2024 | 1 year | NIH | D. Zeng |
| Development of first-in-kind FICD inhibitors | $20,000 | December, 2023 | 1 year | State of Michigan Economic Development Corporation | M. Truttmann |
| FY24-Project V (CHEPS-UM): Healthcare Engineering and Patient Safety | $110,000 | October, 2023 | 1 year | CMS | A. Cohn |
| OPEN Naloxone Distribution and SUD Screening | $270,833 | October, 2023 | 1 year | CDC | C. Brummett, M. Bicket |
| FY24-Project AS (MOMPN-UM): Michigan Opioid Prescribing Engagement Network (M-OPEN) | $3,841,268 | October, 2023 | 1 year | CMS | C. Brummett, A. Bohnert, M. Bicket |
| A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants | $387,010 | October, 2023 | 1 year | AstraZeneca AB | V. Chen |
| Cannabidiol for postoperative Opioid Reduction in primary total Knee arthroplasty – a randomized, 2x2 factorial, double-blind, placebo-controlled clinical trial | $6,088,829 | September, 2023 | 5 years | NIH | C. Brummett |
| Seamless Design for Multicomponent Endpoints for Drug Development in Rare Diseases | $1,151,037 | September, 2023 | 3 years | FDA | K. Kidwell |
| Optimizing Care for Older Adults through Thyroid Hormone Deprescribing | $3,813,622 | September, 2023 | 5 years | NIH | M. Papaleontiou |
| Integrative and trans-ethnic study to understand psoriasis associated signals | $1,885,608 | September, 2023 | 5 years | NIH | L. Tsoi |
| Statistical and Machine Learning Methods to Improve Dynamic Treatment Regimens Estimation Using Real World Data | $1,462,791 | September, 2023 | 3.5 years | NIH | D. Zeng |
| Oral Dysplasias to Carcinomas: Multi-omics Study of Progression | $321,144 | September, 2023 | 2 years | NIH | M. Sartor |
| Machine Learning Methods for Optimizing Individualized Treatment Strategies for Precision Psychiatry | $213,727 | September, 2023 | 2.67 years | NIH | D. Zeng |
| Role of healthy skin molecular phenotype in the switch to specific skin diseases | $10,638 | September, 2023 | 3 years | NIH | L. Tsoi |
| ML Guided Risk Scoring | $232,732 | January, 2023 | 2 years | Schmidt Futures | J. Wiens, M. Makar |